Targeted DNA Vaccine Delivery Systems for Cancer Immunotherapy

Targeted DNA vaccine delivery systems harness genetic material encoding tumour-associated antigens to stimulate robust and specific anti-cancer immune responses. By introducing plasmid DNA into antigen-presenting cells, these vaccines drive in situ synthesis of tumour antigens, fostering both cellular and humoral immunity. The principal challenge lies in efficient and selective transport of DNA to dendritic cells and other professional antigen‐presenting cells within the tumour microenvironment or its draining lymph nodes, while minimising off-target effects and degradation by nucleases. Advances in nanotechnology and bioengineering have led to the development of diverse carriers—lipid-based nanoparticles, polymeric vectors, peptide assemblies and hybrid constructs—that incorporate targeting ligands, stimulus-responsive elements and surface modifications. These innovations enhance cellular uptake, endosomal escape and nuclear delivery of DNA, thereby improving antigen expression and T-cell priming. Furthermore, integration of electroporation or ultrasound can transiently permeabilise cell membranes, boosting transfection efficiency in situ. Collectively, these strategies offer the prospect of personalised immunotherapy with improved safety, repeatability and scalability, addressing unmet needs in the global fight against cancer.

Research from Nature Portfolio

Recent studies have introduced pH-sensitive lipid nanoparticles engineered to accumulate in tumour-draining lymph nodes. These carriers remain stable at physiological pH but undergo membrane fusion under mildly acidic conditions, releasing DNA cargo directly into resident dendritic cells. This approach has yielded enhanced cross-presentation of tumour antigens and potent CD8+ T-cell responses in murine models of melanoma. Another investigation has exploited self-assembling peptide nanofibres decorated with targeting motifs for C-type lectin receptors, achieving selective binding to antigen-presenting cells and sustained antigen expression. The modular design enables rapid adaptation to different tumour antigens, demonstrating broad applicability. A third contribution describes virus-like mesoporous silica nanoparticles coated with a fusogenic peptide, combining high DNA loading capacity with efficient endosomal escape. In preclinical studies, this platform elicited durable tumour regression and immunological memory, highlighting the synergy between structural engineering and biological targeting.

Targeted DNA Vaccine Delivery Systems for Cancer Immunotherapy publication trend

The graph below shows the total number of articles in targeted dna vaccine delivery systems for cancer immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

DNA vaccine: A formulation of plasmid DNA encoding antigenic proteins that, when delivered into host cells, directs in situ antigen synthesis to stimulate an immune response.

Lipid nanoparticle: A vesicular carrier composed of lipid bilayers or micelles designed to encapsulate and protect DNA during delivery and to facilitate cellular uptake and endosomal escape.

Polymeric vector: A synthetic polymer construct, often cationic, that complexes with DNA to form nanoparticles capable of cellular internalisation and nuclear delivery.

Electroporation: A physical method that applies short electrical pulses to cells or tissues to transiently permeabilise membranes, enhancing uptake of nucleic acids.

Antigen-presenting cell (APC): A specialised immune cell, such as a dendritic cell or macrophage, that processes and presents antigenic peptides to T cells, initiating adaptive immunity.

References

1. Haloperidol-associated Stealth Liposomes A POTENT CARRIER FOR DELIVERING GENES TO HUMAN BREAST CANCER CELLS*. Journal of Biological Chemistry (2005).